1
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
Sarah Goldberg, MD, MPH
Medical Oncology, Thoracic Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Biography
Sarah Goldberg, MD, MPH, is a thoracic oncologist who cares for patients with cancers of the chest, including lung cancer. She also treats mesothelioma (cancer that affects the tissue of the lungs, heart, and abdomen) andthymoma(a type of tumor that occurs in the thymus gland, an organ in the upper chest that is part of the lymphatic system).
Dr. Goldberg says caring for patients and offering them the best quality of life are the most rewarding aspects of her job. “I enjoy offering support and care to patients with lung cancer and also getting to know their families,” she says.
She conducts clinical and translational research on lung cancer. The focus of her research is investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific interests include EGFR-positive lung cancer, immunotherapeutics for lung cancer, and brain metastases.
“The field of lung cancer is constantly evolving as new therapies become available,” Dr. Goldberg says.
Titles
- Professor of Internal Medicine (Medical Oncology & Hematology)
- Associate Director, Medical Oncology-Hematology Fellowship Program
- Co-Director, Center for Thoracic Cancers
- Chief, Thoracic Oncology
Education & Training
- FellowDana-Farber Cancer Institute, Massachusetts General Hospital (2012)
- ResidentMassachusetts General Hospital (2009)
- MDMount Sinai School of Medicine (2006)
Additional Information
Publications
- Yu H, Tang K, Markovets A, Hartmaier R, Smith P, Cho B, De Langen A, Goldberg S, Goldman J, Le X, Iwama E, Cosaert J, Riess J, Piotrowska Z. Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study. Clinical Cancer Research 2026, of1-of11. PMID: 41790029, DOI: 10.1158/1078-0432.ccr-25-4540.
- Riess J, Yu H, Le X, de Langen A, Cho B, Piotrowska Z, Hendriks L, Morabito A, Bonanno L, Brustugun O, Halvorsen T, Kim Y, Marrone K, Shiraishi Y, Goldman J, Ambrose H, Smith P, FraenkeI P, Tang K, Lehman J, Goldberg S. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD. Annals Of Oncology 2026 PMID: 41780641, DOI: 10.1016/j.annonc.2026.02.014.
- Cho B, Nishio M, Ahn M, García-Campelo R, Ponce S, Baik C, Salgia R, Kim S, Lee J, Yoshida T, Yu H, Goldberg S, de Langen A, Le X, Piotrowska Z, Riess J, Tanaka K, Ambrose H, Cosaert J, Fraenkel P, Tang K, Lehman J, Smith P, Goldman J. Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD. JTO Clinical And Research Reports 2026, 100937. DOI: 10.1016/j.jtocrr.2025.100937.
- Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24: e257131. PMID: 41698347, PMCID: PMC13112471, DOI: 10.6004/jnccn.2025.7131.
- Le X, Baik C, Cho B, Riess J, Piotrowska Z, Johannes de Langen A, Goldberg S, Goldman J, Reguart N, Shiraishi Y, Ambrose H, Fraenkel P, Ruiz B, Smith P, Tang K, Yu H. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. Journal Of Thoracic Oncology 2025, 21: 318-327. PMID: 41130408, DOI: 10.1016/j.jtho.2025.10.009.
- Halmos B, Florez N, Goldberg S, Iams W, Le X, Leal T, Nguyen D, Raez L, Riess J, Sabari J, Bjork D, Stigger N, Xia Y, Cifuentes P, D’Andrea D, Shanoon F, Johnson A, Johnson M. The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast. Oncology And Therapy 2025, 13: 871-880. PMID: 41075104, PMCID: PMC12647402, DOI: 10.1007/s40487-025-00386-8.
- Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.
- Riess J, de Langen A, Ponce S, Goldberg S, Piotrowska Z, Goldman J, Le X, Cho B, Yoneshima Y, Ambrose H, Cavazzina R, Tang K, Lau J, Yu H. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology 2025, 9: e2400818. PMID: 40466026, DOI: 10.1200/po-24-00818.
- Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.
- Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.
- Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025, 31: 2767-2776. PMID: 40047548, PMCID: PMC12213210, DOI: 10.1158/1078-0432.ccr-24-3347.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response to Letter to the Editor From Drs. Xiaowei Huang, Xian Gu, and Zhenye Xu. Journal Of Thoracic Oncology 2025, 20: e2-e3. PMID: 39794113, DOI: 10.1016/j.jtho.2024.10.011.
- Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer After Progression on Osimertinib. Clinical Lung Cancer 2024, 26: 9-17.e3. PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.
- Robichaux J, Elamin Y, Tan Z, Carter B, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le A, Truini A, Nilsson M, Sun H, Roarty E, Goldberg S, Brahmer J, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele R, Wong K, Heymach J. Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nature Medicine 2024, 30: 2694-2695. PMID: 39164519, DOI: 10.1038/s41591-024-03178-1.
- Weller M, Remon J, Rieken S, Vollmuth P, Ahn M, Minniti G, Le Rhun E, Westphal M, Brastianos P, Soo R, Kirkpatrick J, Goldberg S, Öhrling K, Hegi-Johnson F, Hendriks L. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape. Cancer Treatment Reviews 2024, 130: 102807. PMID: 39151281, DOI: 10.1016/j.ctrv.2024.102807.
- Pike L, Miao E, Boe L, Patil T, Imber B, Myall N, Pollom E, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg S, Palmer J, Prasad R, Wang T, Lee A, Shu C, Chen L, Thomas N, Braunstein S, Kavanagh B, Camidge D, Rusthoven C. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC). Journal Of Clinical Oncology 2024, 42: 3606-3617. PMID: 39047224, PMCID: PMC11874932, DOI: 10.1200/jco.23.02668.
- Barlesi F, Cho B, Goldberg S, Yoh K, Gelatti A, Mann H, Gopinathan A, Bielecka Z, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncology 2024, 20: 2137-2147. PMID: 39023287, PMCID: PMC11508940, DOI: 10.1080/14796694.2024.2354160.
- Amouzegar A, Haig S, Kahn A, Tawbi H, Jones J, Goldberg S. Navigating the Complexities of Brain Metastases Management. American Society Of Clinical Oncology Educational Book 2024, 44: e433694. PMID: 38781565, DOI: 10.1200/edbk_433694.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response letter by Nassar et al. Journal Of Thoracic Oncology 2024, 19: e7-e8. PMID: 38719428, DOI: 10.1016/j.jtho.2024.03.013.
- Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, PMCID: PMC12279297, DOI: 10.1007/s13187-024-02414-z.
- Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.
- Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.
- Liu S, Elkins I, Feldman J, Goldberg S. EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists. Oncology And Therapy 2023, 11: 419-431. PMID: 37750968, PMCID: PMC10673799, DOI: 10.1007/s40487-023-00242-7.
- Lu B, Goldberg S. Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy? Journal Of Clinical Oncology 2023, 41: 4462-4464. PMID: 37603819, DOI: 10.1200/jco.23.01323.
- Grant M, Goldberg S. Precise, pragmatic and inclusive: the modern era of oncology clinical trials. Nature Medicine 2023, 29: 1908-1909. PMID: 37524954, DOI: 10.1038/s41591-023-02466-6.
- Goldberg S, Herbst R. Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: i. DOI: 10.1016/s0889-8588(23)00027-8.
- Garon E, Spira A, Goldberg S, Chaft J, Papadimitrakopoulou V, Cascone T, Antonia S, Brahmer J, Camidge D, Powderly J, Wozniak A, Felip E, Wu S, Ascierto M, Elgeioushi N, Awad M. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. Journal Of Thoracic Oncology 2023, 18: 1094-1102. PMID: 37146752, DOI: 10.1016/j.jtho.2023.04.020.
- Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo J, Dennis M, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess J, Kim S, Goldberg S, Li M, Wang Q, Qing Y, Ni Y, Truong M, Lee R, Ricciuti B, Alessi J, Wang J, Resuli B, Landi L, Tseng S, Nishino M, Digumarthy S, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan A, Blumenschein G, Zhang J, Owen D, Blakely C, Mountzios G, Shu C, Bestvina C, Garassino M, Marrone K, Gray J, Patel S, Cummings A, Wakelee H, Wolf J, Scagliotti G, Cappuzzo F, Barlesi F, Patil P, Drusbosky L, Gibbons D, Meric-Bernstam F, Lee J, Heymach J, Hong D, Heist R, Awad M, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery 2023, 13: 1556-1571. PMID: 37068173, PMCID: PMC11024958, DOI: 10.1158/2159-8290.cd-22-1420.
- Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.
- Goldberg S, Herbst R. Advances and Opportunities in the Management of Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: xi-xii. PMID: 37024390, DOI: 10.1016/j.hoc.2023.03.001.
- Rizvi N, Ademuyiwa F, Cao Z, Chen H, Ferris R, Goldberg S, Hellmann M, Mehra R, Rhee I, Park J, Kluger H, Tawbi H, Sullivan R. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Journal For ImmunoTherapy Of Cancer 2023, 11: e005920. PMID: 36918220, PMCID: PMC10016262, DOI: 10.1136/jitc-2022-005920.
- Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.
- Goldberg S, Herbst R. The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer. The Lancet 2023, 401: 706-707. PMID: 36774937, DOI: 10.1016/s0140-6736(23)00288-x.
- Merkin R, Chiang V, Goldberg S. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances In Medical Oncology 2023, 15: 17588359231175438. PMID: 37275964, PMCID: PMC10233588, DOI: 10.1177/17588359231175438.
- Hwang M, Chia Y, Zheng Y, Chen C, He J, Song X, Zhou D, Goldberg S, Siu L, Planchard D, Peters S, Mann H, Krug L, Even C. Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance. British Journal Of Clinical Pharmacology 2022, 89: 1601-1616. PMID: 36454221, DOI: 10.1111/bcp.15622.
- van Alderwerelt van Rosenburgh I, Lu D, Grant M, Stayrook S, Phadke M, Walther Z, Goldberg S, Politi K, Lemmon M, Ashtekar K, Tsutsui Y. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications 2022, 13: 6791. PMID: 36357385, PMCID: PMC9649653, DOI: 10.1038/s41467-022-34398-z.
- Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung. 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.
- Kaulen L, Lu B, Goldberg S, Baehring J. Chapter 15 Neurological complications of lung cancer. 2022, 243-276. DOI: 10.1016/b978-0-12-821976-8.00027-x.
- Collier E, Chiang V, Goldberg S. Management of Brain Metastases. Current Cancer Research 2021, 115-137. DOI: 10.1007/978-3-030-74028-3_6.
- Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.
- Cheok S, Arnal-Estape A, Narayan A, Zakaria M, Goldberg S, Patel A, Nguyen D, Chiang V. Cerebrospinal Fluid Biomarkers of Brain Metastasis. Neurosurgery 2019, 66: 310-631. DOI: 10.1093/neuros/nyz310_631.
Departments and Programs
Locations
1
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
Biography
Sarah Goldberg, MD, MPH, is a thoracic oncologist who cares for patients with cancers of the chest, including lung cancer. She also treats mesothelioma (cancer that affects the tissue of the lungs, heart, and abdomen) andthymoma(a type of tumor that occurs in the thymus gland, an organ in the upper chest that is part of the lymphatic system).
Dr. Goldberg says caring for patients and offering them the best quality of life are the most rewarding aspects of her job. “I enjoy offering support and care to patients with lung cancer and also getting to know their families,” she says.
She conducts clinical and translational research on lung cancer. The focus of her research is investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific interests include EGFR-positive lung cancer, immunotherapeutics for lung cancer, and brain metastases.
“The field of lung cancer is constantly evolving as new therapies become available,” Dr. Goldberg says.
Titles
- Professor of Internal Medicine (Medical Oncology & Hematology)
- Associate Director, Medical Oncology-Hematology Fellowship Program
- Co-Director, Center for Thoracic Cancers
- Chief, Thoracic Oncology
Education & Training
- FellowDana-Farber Cancer Institute, Massachusetts General Hospital (2012)
- ResidentMassachusetts General Hospital (2009)
- MDMount Sinai School of Medicine (2006)
Additional Information
Publications
- Yu H, Tang K, Markovets A, Hartmaier R, Smith P, Cho B, De Langen A, Goldberg S, Goldman J, Le X, Iwama E, Cosaert J, Riess J, Piotrowska Z. Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study. Clinical Cancer Research 2026, of1-of11. PMID: 41790029, DOI: 10.1158/1078-0432.ccr-25-4540.
- Riess J, Yu H, Le X, de Langen A, Cho B, Piotrowska Z, Hendriks L, Morabito A, Bonanno L, Brustugun O, Halvorsen T, Kim Y, Marrone K, Shiraishi Y, Goldman J, Ambrose H, Smith P, FraenkeI P, Tang K, Lehman J, Goldberg S. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD. Annals Of Oncology 2026 PMID: 41780641, DOI: 10.1016/j.annonc.2026.02.014.
- Cho B, Nishio M, Ahn M, García-Campelo R, Ponce S, Baik C, Salgia R, Kim S, Lee J, Yoshida T, Yu H, Goldberg S, de Langen A, Le X, Piotrowska Z, Riess J, Tanaka K, Ambrose H, Cosaert J, Fraenkel P, Tang K, Lehman J, Smith P, Goldman J. Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD. JTO Clinical And Research Reports 2026, 100937. DOI: 10.1016/j.jtocrr.2025.100937.
- Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24: e257131. PMID: 41698347, PMCID: PMC13112471, DOI: 10.6004/jnccn.2025.7131.
- Le X, Baik C, Cho B, Riess J, Piotrowska Z, Johannes de Langen A, Goldberg S, Goldman J, Reguart N, Shiraishi Y, Ambrose H, Fraenkel P, Ruiz B, Smith P, Tang K, Yu H. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. Journal Of Thoracic Oncology 2025, 21: 318-327. PMID: 41130408, DOI: 10.1016/j.jtho.2025.10.009.
- Halmos B, Florez N, Goldberg S, Iams W, Le X, Leal T, Nguyen D, Raez L, Riess J, Sabari J, Bjork D, Stigger N, Xia Y, Cifuentes P, D’Andrea D, Shanoon F, Johnson A, Johnson M. The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast. Oncology And Therapy 2025, 13: 871-880. PMID: 41075104, PMCID: PMC12647402, DOI: 10.1007/s40487-025-00386-8.
- Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.
- Riess J, de Langen A, Ponce S, Goldberg S, Piotrowska Z, Goldman J, Le X, Cho B, Yoneshima Y, Ambrose H, Cavazzina R, Tang K, Lau J, Yu H. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology 2025, 9: e2400818. PMID: 40466026, DOI: 10.1200/po-24-00818.
- Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.
- Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.
- Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025, 31: 2767-2776. PMID: 40047548, PMCID: PMC12213210, DOI: 10.1158/1078-0432.ccr-24-3347.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response to Letter to the Editor From Drs. Xiaowei Huang, Xian Gu, and Zhenye Xu. Journal Of Thoracic Oncology 2025, 20: e2-e3. PMID: 39794113, DOI: 10.1016/j.jtho.2024.10.011.
- Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer After Progression on Osimertinib. Clinical Lung Cancer 2024, 26: 9-17.e3. PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.
- Robichaux J, Elamin Y, Tan Z, Carter B, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le A, Truini A, Nilsson M, Sun H, Roarty E, Goldberg S, Brahmer J, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele R, Wong K, Heymach J. Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nature Medicine 2024, 30: 2694-2695. PMID: 39164519, DOI: 10.1038/s41591-024-03178-1.
- Weller M, Remon J, Rieken S, Vollmuth P, Ahn M, Minniti G, Le Rhun E, Westphal M, Brastianos P, Soo R, Kirkpatrick J, Goldberg S, Öhrling K, Hegi-Johnson F, Hendriks L. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape. Cancer Treatment Reviews 2024, 130: 102807. PMID: 39151281, DOI: 10.1016/j.ctrv.2024.102807.
- Pike L, Miao E, Boe L, Patil T, Imber B, Myall N, Pollom E, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg S, Palmer J, Prasad R, Wang T, Lee A, Shu C, Chen L, Thomas N, Braunstein S, Kavanagh B, Camidge D, Rusthoven C. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC). Journal Of Clinical Oncology 2024, 42: 3606-3617. PMID: 39047224, PMCID: PMC11874932, DOI: 10.1200/jco.23.02668.
- Barlesi F, Cho B, Goldberg S, Yoh K, Gelatti A, Mann H, Gopinathan A, Bielecka Z, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncology 2024, 20: 2137-2147. PMID: 39023287, PMCID: PMC11508940, DOI: 10.1080/14796694.2024.2354160.
- Amouzegar A, Haig S, Kahn A, Tawbi H, Jones J, Goldberg S. Navigating the Complexities of Brain Metastases Management. American Society Of Clinical Oncology Educational Book 2024, 44: e433694. PMID: 38781565, DOI: 10.1200/edbk_433694.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response letter by Nassar et al. Journal Of Thoracic Oncology 2024, 19: e7-e8. PMID: 38719428, DOI: 10.1016/j.jtho.2024.03.013.
- Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, PMCID: PMC12279297, DOI: 10.1007/s13187-024-02414-z.
- Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.
- Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.
- Liu S, Elkins I, Feldman J, Goldberg S. EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists. Oncology And Therapy 2023, 11: 419-431. PMID: 37750968, PMCID: PMC10673799, DOI: 10.1007/s40487-023-00242-7.
- Lu B, Goldberg S. Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy? Journal Of Clinical Oncology 2023, 41: 4462-4464. PMID: 37603819, DOI: 10.1200/jco.23.01323.
- Grant M, Goldberg S. Precise, pragmatic and inclusive: the modern era of oncology clinical trials. Nature Medicine 2023, 29: 1908-1909. PMID: 37524954, DOI: 10.1038/s41591-023-02466-6.
- Goldberg S, Herbst R. Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: i. DOI: 10.1016/s0889-8588(23)00027-8.
- Garon E, Spira A, Goldberg S, Chaft J, Papadimitrakopoulou V, Cascone T, Antonia S, Brahmer J, Camidge D, Powderly J, Wozniak A, Felip E, Wu S, Ascierto M, Elgeioushi N, Awad M. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. Journal Of Thoracic Oncology 2023, 18: 1094-1102. PMID: 37146752, DOI: 10.1016/j.jtho.2023.04.020.
- Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo J, Dennis M, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess J, Kim S, Goldberg S, Li M, Wang Q, Qing Y, Ni Y, Truong M, Lee R, Ricciuti B, Alessi J, Wang J, Resuli B, Landi L, Tseng S, Nishino M, Digumarthy S, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan A, Blumenschein G, Zhang J, Owen D, Blakely C, Mountzios G, Shu C, Bestvina C, Garassino M, Marrone K, Gray J, Patel S, Cummings A, Wakelee H, Wolf J, Scagliotti G, Cappuzzo F, Barlesi F, Patil P, Drusbosky L, Gibbons D, Meric-Bernstam F, Lee J, Heymach J, Hong D, Heist R, Awad M, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery 2023, 13: 1556-1571. PMID: 37068173, PMCID: PMC11024958, DOI: 10.1158/2159-8290.cd-22-1420.
- Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.
- Goldberg S, Herbst R. Advances and Opportunities in the Management of Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: xi-xii. PMID: 37024390, DOI: 10.1016/j.hoc.2023.03.001.
- Rizvi N, Ademuyiwa F, Cao Z, Chen H, Ferris R, Goldberg S, Hellmann M, Mehra R, Rhee I, Park J, Kluger H, Tawbi H, Sullivan R. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Journal For ImmunoTherapy Of Cancer 2023, 11: e005920. PMID: 36918220, PMCID: PMC10016262, DOI: 10.1136/jitc-2022-005920.
- Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.
- Goldberg S, Herbst R. The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer. The Lancet 2023, 401: 706-707. PMID: 36774937, DOI: 10.1016/s0140-6736(23)00288-x.
- Merkin R, Chiang V, Goldberg S. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances In Medical Oncology 2023, 15: 17588359231175438. PMID: 37275964, PMCID: PMC10233588, DOI: 10.1177/17588359231175438.
- Hwang M, Chia Y, Zheng Y, Chen C, He J, Song X, Zhou D, Goldberg S, Siu L, Planchard D, Peters S, Mann H, Krug L, Even C. Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance. British Journal Of Clinical Pharmacology 2022, 89: 1601-1616. PMID: 36454221, DOI: 10.1111/bcp.15622.
- van Alderwerelt van Rosenburgh I, Lu D, Grant M, Stayrook S, Phadke M, Walther Z, Goldberg S, Politi K, Lemmon M, Ashtekar K, Tsutsui Y. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications 2022, 13: 6791. PMID: 36357385, PMCID: PMC9649653, DOI: 10.1038/s41467-022-34398-z.
- Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung. 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.
- Kaulen L, Lu B, Goldberg S, Baehring J. Chapter 15 Neurological complications of lung cancer. 2022, 243-276. DOI: 10.1016/b978-0-12-821976-8.00027-x.
- Collier E, Chiang V, Goldberg S. Management of Brain Metastases. Current Cancer Research 2021, 115-137. DOI: 10.1007/978-3-030-74028-3_6.
- Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.
- Cheok S, Arnal-Estape A, Narayan A, Zakaria M, Goldberg S, Patel A, Nguyen D, Chiang V. Cerebrospinal Fluid Biomarkers of Brain Metastasis. Neurosurgery 2019, 66: 310-631. DOI: 10.1093/neuros/nyz310_631.
Departments and Programs
Locations
1
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
1
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473